PubMed Health⌕ Search

PubMed · 11197664

Motion adaptive x-ray therapy: a feasibility study.

Abstract

Intrafraction motion caused by breathing requires increased treatment margins for chest and abdominal radiotherapy and may lead to 'motion artefacts' in dose distributions during intensity modulated radiotherapy (IMRT). Technologies such as gated radiotherapy may significantly increase the treatment time, while breath-hold techniques may be poorly tolerated by pulmonarily compromised patients. A solution that allows reduced margins and dose distribution artefacts, without compromising delivery time, is to synchronously follow the target motion by adapting the x-ray beam using a dynamic multileaf collimator (MLC), i.e. motion adaptive x-ray therapy, or MAX-T for short. Though the target is moving with time, in the MAX-T beam view the target is static. The MAX-T method superimposes the target motion due to respiration onto the beam originally planned for delivery. Thus during beam delivery the beam is dynamically changing position with respect to the isocentre using a dynamic MLC, the leaf positions of which are dependent upon the target position. Synchronization of the MLC motion and target motion occurs using respiration gated radiotherapy equipment. The concept and feasibility of MAX-T and the capability of the treatment machine to deliver such a treatment were investigated by performing measurements for uniform and IMRT fields using a mechanical sinusoidal oscillator to simulate target motion. Target dose measurements obtained using MAX-T for a moving target were found to be equivalent to those delivered to a static target by a static beam.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P J Keall, V R Kini, S S Vedam, R Mohan. 2001. Motion adaptive x-ray therapy: a feasibility study.. https://doi.org/10.1088/0031-9155%2F46%2F1%2F301

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A feasibility study on the use of visible and short wavelengths in the near-infrared region for the non-destructive measurement of wine composition.

The aim of this study was to explore the capability of spectroscopy in the visible (Vis) and short wavelength near-infrared (NIR) regions for the non-destructive measurement of wine composition in intact bottles. In this study we analysed a wide range of commercial wines obtained in Australia in different types of bottles (e.g. colours, diameters and heights), including different wine styles and varieties. Wine bottles were scanned in the Vis-NIR region (600-1,100 nm) in a monochromator instrument in transflectance mode. Principal component analysis (PCA) and partial least-squares (PLS) regression were used to interpret the spectra and develop calibrations for wine composition. Due to the relatively small number of samples available full cross-validation (leave-one-out) was used as validation. The coefficient of correlation in calibration [Formula: see text] and the standard error of cross-validation (SECV) were 0.67 (SECV: 0.48%), 0.83 (SECV: 4.01 mg L-1), 0.70 (SECV: 28.6 mg L-1) and 0.50 (SECV: 0.15) for alcohol content, total SO2, free SO2 and pH, respectively, in the set of wine samples analysed. These preliminary results showed that the assessment of wine composition by Vis and short wavelengths in the NIR is possible for either qualitative analysis (e.g. low-, medium- and high-quality grading), or for screening of composition during bottling and storage. Although low accuracy and precision were obtained for the chemical parameters routinely analysed in wine, calibration models for the chemical parameters were considered acceptable for screening purposes in terms of the standard errors obtained.

Feasibility Studies↗

Image-guided in vivo dosimetry for quality assurance of IMRT treatment for prostate cancer.

PURPOSE: In external beam radiotherapy (EBRT) and especially in intensity-modulated radiotherapy (IMRT), the accuracy of the dose distribution in the patient is of utmost importance. It was investigated whether image guided in vivo dosimetry in the rectum is a reliable method for online dose verification. METHODS AND MATERIALS: Twenty-one dose measurements were performed with an ionization chamber in the rectum of 7 patients undergoing IMRT for prostate cancer. The position of the probe was determined with cone beam computed tomography (CBCT). The point of measurement was determined relative to the isocenter and relative to an anatomic reference point. The dose deviations relative to the corresponding doses in the treatment plan were calculated. With an offline CT soft-tissue match, patient positioning after ultrasound was verified. RESULTS: The mean magnitude +/- standard deviation (SD) of patient positioning errors was 3.0 +/- 2.5 mm, 5.1 +/- 4.9 mm, and 4.3 +/- 2.4 mm in the left-right, anteroposterior and craniocaudal direction. The dose deviations in points at corresponding positions relative to the isocenter were -1.4 +/- 4.9% (mean +/- SD). The mean dose deviation at corresponding anatomic positions was 6.5 +/- 21.6%. In the rare event of insufficient patient positioning, dose deviations could be >30% because of the close proximity of the probe and the posterior dose gradient. CONCLUSIONS: Image-guided dosimetry in the rectum during IMRT of the prostate is a feasible and reliable direct method for dose verification when probe position is effectively controlled.

Feasibility Studies↗